An article posted on Doctor's Guide News entitled Once-daily Armodafinil sustains wakefulness throughout the day reports on a study by Russell Rosenberg, PhD, Atlanta School of Sleep Medicine and Technology, Atlanta, Georgia Armodafinil found Armodafinil, a wakefulness-promoting agent approved by the US Food and Drug Administration (FDA) for narcolepsy, shiftwork sleep disorder, obstructive sleep apnea, found "Armodafinil offers an advantage to patients with excess sleepiness compared to modafinil by providing efficacy at a lower dose and sustained benefits many hours post-dose."
Subscribe to:
Post Comments (Atom)
Posts
View Ed Coburn's profile
No comments:
Post a Comment